Edition:
United Kingdom

Syros Pharmaceuticals Inc (SYRS.OQ)

SYRS.OQ on NASDAQ Stock Exchange Global Select Market

10.85USD
7:05pm GMT
Change (% chg)

$0.33 (+3.14%)
Prev Close
$10.52
Open
$10.58
Day's High
$10.89
Day's Low
$10.53
Volume
25,605
Avg. Vol
92,740
52-wk High
$24.35
52-wk Low
$6.31

Select another date:

Mon, Jan 8 2018

BRIEF-Incyte Corp - Co, Syros Pharmaceuticals Have Entered Into Target Discovery, Research Collaboration And Option Agreement

* INCYTE CORP - CO, SYROS PHARMACEUTICALS HAVE ENTERED INTO A TARGET DISCOVERY, RESEARCH COLLABORATION AND OPTION AGREEMENT

BRIEF-Syros Announces 2018 Strategic Priorities And Expected Milestones

* SYROS ANNOUNCES 2018 STRATEGIC PRIORITIES AND EXPECTED MILESTONES

BRIEF-Syros Announces Clinical Supply Agreement With Janssen To Evaluate SY-1425

* SYROS ANNOUNCES CLINICAL SUPPLY AGREEMENT WITH JANSSEN TO EVALUATE SY-1425, ITS FIRST-IN-CLASS SELECTIVE RARΑ AGONIST, IN COMBINATION WITH DARATUMUMAB IN GENOMICALLY DEFINED AML AND MDS PATIENTS

BRIEF-Syros Pharma Q3 loss per share $0.53

* Syros reports third quarter 2017 financial results and highlights accomplishments and upcoming milestones

BRIEF-SYROS PHARMACEUTICALS PRESENTS BIOMARKER DATA FROM ONGOING PHASE 2 TRIAL OF SY-1425

* SYROS PHARMACEUTICALS INC - PRESENTS BIOMARKER DATA FROM ITS ONGOING PHASE 2 CLINICAL TRIAL OF SY-1425 IN GENOMICALLY DEFINED AML AND MDS PATIENTS

BRIEF-Syros Pharmaceuticals says board appointed CEO Nancy Simonian as company's principal financial officer - SEC Filing

* Syros Pharmaceuticals says on Sept 28 board appointed Nancy Simonian, co's president and CEO, as company's principal financial officer - SEC Filing Source text: [http://bit.ly/2hAgfq3] Further company coverage:

BRIEF-Syros pharmaceuticals - ‍expects to present initial phase 2 clinical data for SY-1425 in Q4 of 2017​

* Syros pharmaceuticals - ‍expects to present initial phase 2 clinical data for SY-1425 in Q4 of 2017​ Source text for Eikon: Further company coverage:

BRIEF-Syros receives FDA Orphan drug designation for SY-1425 for treatment of AML

* Syros receives fda orphan drug designation for SY-1425 for treatment of AML

BRIEF-Syros Pharmaceuticals Q2 loss per share $0.52

* Syros reports second quarter 2017 financial results and highlights accomplishments and upcoming milestones

BRIEF-Syros publishes foundational data supporting phase 2 clinical trial

* Syros publishes foundational data supporting ongoing phase 2 clinical trial of SY-1425 for genomically defined AML and MDS patients

Select another date: